As shown in Fig. 2A where the results from individual samples are plotted, this preliminary screen suggested that STAMP levels in kidney cancers gradually decrease as the tumor stage progresses while STAMP levels might be elevated in Stage I of ovarian cancers and several stages of breast cancer. Here, TTLL5 is linked to breast carcinoma.